Class II MHC Protein and Tetramer Core

II 类 MHC 蛋白和四聚体核心

• 批准号: 7698599
• 负责人: Lawrence J. Stern
• 金额: $ 18.09万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-15 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7698599
• 关键词: Alleles; Antigens; CD4 Positive T Lymphocytes; Categories; Complex; Core Facility; Development; HLA-DR1 Antigen; Histocompatibility Antigens Class II; Human; MHC Class II Genes; Peptide/MHC Complex; Peptides; Production; Proteins; Reagent; Recombinants; Research Project Grants; Support of Research; T-Lymphocyte; T-Lymphocyte Epitopes; Virus; new technology; reagent testing; response

The Class II MHC Protein and Tetramer Core will support Research Projects 1-3 and the TDC by providing Class II MHC proteins and tetramers carrying Category A-C agent peptides. The specific aims of the proposed core facility are to generate HLA-DRl-peptide tetramers for use in quantifying and characterizing CD4+ T cells responding to category A-C viruses, to generate purified HLA-DRl-peptide complexes for use in development of microassays to detect CD4+ T cells, and to investigate the production of human class II MHC proteins other than HLA-DR1 for use as purified MHC-peptide complexes and tetramers. These are specialized reagents not available commercially. Production in a core facility will provide economies of scale, standardized production, and reagent testing, and will facilitate production of additional alleles. The ready availability of HLA-DR-peptide proteins and tetramers should greatly enhance the ability of the Research Projects to enumerate, isolate, and characterize virus-specific CD4+ T cell responses, and the ability of the TDC to develop and validate new technology for identification of T cell epitopes and characterization of antigen-specific T cell functional responses.

II类MHC蛋白和四聚体核心将支持研究项目1-3和TDC 通过提供II类MHC蛋白和四聚体携带A-C试剂肽类别。这 所提出的核心设施的具体目的是生成HLA-DRL肽四聚体 在量化和表征CD4+ T细胞响应A-C病毒的CD4+ T细胞中 生成纯化的HLA-DRL肽复合物，用于开发微观测定 检测CD4+ T细胞，并研究人类II类MHC蛋白的产生其他 比HLA-DR1用作纯化的MHC肽复合物和四聚体。这些都是 专门的试剂在商业上不可用。核心设施的生产将提供 规模经济，标准化生产和试剂测试，并将促进生产 其他等位基因。 HLA-DR肽蛋白和四聚体的现成可用性应 极大地增强了研究项目枚举，隔离和特征的能力 病毒特异性的CD4+ T细胞反应，以及TDC发展和验证新的能力 鉴定T细胞表位的技术和抗原特异性T细胞的表征 功能响应。